Dermatologic adverse events related to the PI3Kalpha inhibitor alpelisib (BYL719) in patients with breast cancer. Wang DG, Barrios DM, Blinder VS, Bromberg JF, et al. Breast Cancer Res Treat 2020 Jun 29. pii: 10.1007/s10549-020-05726.

Read + Share

Amedeo Smart

Independent Medical Education

Wang DG, Barrios DM, Blinder VS, Bromberg JF, et al. Dermatologic adverse events related to the PI3Kalpha inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat 2020 Jun 29. pii: 10.1007/s10549-020-05726.
PMID: 32613539